Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
Financial Results:
Aurobindo Pharma Ltd reported Revenues for Q2FY24 of ₹7,219.00 Crores up from ₹5,739.00 Crore year on year, a rise of 25.79%.
Total Expenses for Q2FY24 of ₹6,332.00 Crores up from ₹5,273.00 Crores year on year, a rise of 20.08%.
Consolidated Net Profit of ₹752.00 Crores up 83.41% from ₹410.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹12.92, up 84.84% from ₹6.99 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.